Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial
Kathryn M Field, Greg Fitt, Mark A Rosenthal, John Simes, Anna K Nowak, Elizabeth H Barnes, Kate Sawkins, Christine Goh, Bradford A Moffat, Simon Salinas, Lawrence Cher, Helen Wheeler, Elizabeth J Hovey, Pramit M Phal
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2018
AIM: Assessment of magnetic resonance imaging (MRI) in glioblastoma can be challenging. For patients with recurrent glioblastoma managed on the CABARET trial, we compared disease status assessed at hospitals and subsequent blinded central expert radiological review. METHODS: MRI results and clinical status at specified time points were used for site and central assessment of disease status. Clinical status was determined by the site. Response Assessment in Neuro-Oncology (RANO) criteria were used for both assessments. Site and central assessments of progression-free survival (PFS) and response rates were compared. Inter-rater variability for central review progression dates was assessed. RES..View full abstract
Awarded by National Health and Medical Research Council
Roche Products Australia Pty Ltd and National Health and Medical Research Council (1037786).